Latest news with #RedChipCompanies
Miami Herald
23-05-2025
- Business
- Miami Herald
FatPipe and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / May 23, 2025 / RedChip Companies will air interviews with FatPipe, Inc. (Nasdaq:FATN) and Foremost Clean Energy (Nasdaq:FMST) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: FATN: In an exclusive interview, Dr. Ragula Bhaskar, CEO of FatPipe, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is transforming enterprise connectivity through its patented, software-defined networking technologies. With a product suite spanning SD-WAN, Secure Access Service Edge (SASE), and Network Monitoring Services (NMS), FatPipe enables over 2,500 customers-including government agencies, financial institutions, and healthcare providers-to unify, secure, and optimize their networks across cloud, hybrid, and on-premise environments. Dr. Bhaskar highlights FatPipe's robust financial performance, including $17.9 million in revenue and $4.4 million in net income for fiscal 2024, and outlines the company's growth strategy focused on global expansion, product innovation, and deepening its high-margin, subscription-based revenue model. Positioned at the intersection of three multi-billion-dollar markets and operating as a "Rule of 40" business, FatPipe offers investors a compelling blend of profitability, scalability, and exposure to the accelerating digital infrastructure megatrend. Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share the company's strategic vision for advancing uranium exploration in the world-renowned Athabasca Basin. Barnard details Foremost's expansive portfolio of 10 uranium properties spanning over 330,000 acres, including high-priority drill targets at Hatchet Lake and Murphy Lake South, where recent assays confirm strong mineralization and discovery potential. He also discusses the company's transformational partnership with Denison Mines, which brings technical, financial, and strategic backing from a C$2.9 billion uranium leader with a 19.13% equity stake in Foremost. With nuclear energy gaining momentum as a critical clean power source-and global pledges to triple capacity by 2050-Foremost is uniquely positioned to benefit from structural supply deficits and surging demand. Barnard highlights the company's fully funded 2025 exploration program, robust institutional backing, and dual exposure to uranium and lithium as key drivers of long-term shareholder value. FATN and FMST are clients of RedChip Companies. Please read our full disclosure at About FatPipe, Inc. FatPipe pioneered the concept of software-defined wide area networking (SD-WAN) and hybrid WANs that eliminate the need for hardware and software or cooperation from ISPs and allows companies and service providers to control multi-link network traffic. FatPipe currently has 12 U.S. patents related to multipath, software-defined networking. FatPipe products are sold by 200+ resellers worldwide. For more information, visit Follow us on X @FatPipe_Inc. To learn more, visit or contact sales321@ About Foremost Foremost Clean Energy Ltd. (NASDAQ:FMST)(CSE:FAT)(WKN:A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec. For further information, please visit the Company's website at About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc.
Associated Press
07-05-2025
- Automotive
- Associated Press
Phoenix Motor to Discuss 2024 Financial Results During Webinar on June 4
A live Q&A session with management will follow the company's prepared remarks ANAHEIM, CA / ACCESS Newswire / May 7, 2025 / Phoenix Motor Inc. (OTC PINK:PEVM), a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, is pleased to invite investors to a webinar on June 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Phoenix Motor CEO Denton Peng, CFO Michael Yung, COO Lewis Liu, CRO Jose Paul Plackal, and CTO Tony Zhou. Phoenix Motor's leadership team will discuss the company's fiscal year 2024 financial results and provide insight into the company's position as a leader in zero-emission, all-electric commercial transportation solutions. For 2024, Phoenix Motor projects revenue of $30.7 million to $31.2 million, a more than tenfold increase from $3 million in 2023, with the company also expecting to report positive net income-a dramatic turnaround from its net loss in the prior year. Looking ahead, 2025 revenue is projected to be in the range of $40 million to $50 million, reflecting continued market expansion and strong demand for Phoenix's zero-emission commercial vehicle solutions. A live question and answer session will follow the presentation. To register for the free webinar, please visit: Questions can be pre-submitted to [email protected] or online during the live event. About Phoenix Motor Inc. Phoenix Motor, a pioneer in the electric vehicle ('EV') industry, designs, builds, and integrates electric drive systems and manufactures heavy duty transit buses and medium and light duty commercial EVs. Phoenix operates two primary brands, 'Phoenix', which is focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school buses and delivery trucks, among others) and 'EdisonFuture', which intends to offer light-duty EVs. Phoenix endeavors to be a leading designer, developer and manufacturer of electric vehicles and electric vehicle technologies. To learn more, please visit: . Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as 'may,' 'might,' 'will,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'continue,' 'expect,' 'believe,' 'anticipate,' 'estimate,' 'predict,' 'outlook,' 'potential,' 'plan,' 'seek,' and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company's current expectations and speak only as of the date of this release. Actual results may differ materially from the Company's current expectations depending upon a number of factors. These risk factors include, among others, those related to our ability to raise additional capital necessary to grow our business, operations and business and financial performance, our ability to grow demand for our products and revenue, our ability to become profitable, our ability to have access to an adequate supply of parts and materials and other critical components for our vehicles on the timeline we expect, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the 'Risk Factors' section of the Company's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements. Contact: [email protected] Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 [email protected] SOURCE: Phoenix Motor Inc. press release
Associated Press
17-04-2025
- Business
- Associated Press
ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / April 17, 2025 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, April 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: In an exclusive interview, Paul Mann, Chief Executive Officer of ASP Isotopes, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's strategic roadmap, breakthrough enrichment technologies, and expanding commercial footprint. Mann will share updates on the Company's three flagship facilities in South Africa: the Carbon-14 plant, which recently began commercial production under a multi-year contract; the Silicon-28 facility, designed to enable next-generation semiconductors for AI and quantum computing; and the Ytterbium-176 plant, which supports advanced radiopharmaceuticals for cancer therapy. These state-of-the-art operations mark ASP Isotopes' evolution from an R&D-stage innovator to a commercial supplier-positioning the Company as a key Western source for critical isotopes in healthcare, semiconductors, and nuclear energy. Maria Zannes, President and CEO of bioAffinity, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath® Lung. CyPath® Lung improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath® Lung, making the test available to U.S. veterans and federal health service patients, which is expected to accelerate sales growth in the quarters ahead. ASPI and BIAF are clients of RedChip Companies. Please read our full disclosure at About ASP Isotopes, Inc. ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ('ASP technology'). The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes). There is a growing demand for isotopes such as Silicon-28 for enabling quantum computing; Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, Lithium-7 and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. To learn more about RedChip's products and services, please visit: 'Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave Gentry RedChip Companies Inc. 1-407-644-4256 [email protected] SOURCE: RedChip Companies, Inc. (Media Suite) press release
Associated Press
16-02-2025
- Business
- Associated Press
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with Aptevo Therapeutics' (Nasdaq:APVO) President and CEO Marvin White, will air on RedChip's Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, Saturday, February 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interview in its entirety: In an exclusive interview, Marvin White, President and CEO of Aptevo, will appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's recent accomplishments and innovative approach to the development of bispecific immuno-oncology therapeutics that are differentiated by design. Lead candidate, Mipletamig (CD3 x CD123)targets AML (a $6.3B market) and has treated more than 100 patients across three clinical trials and consistently demonstrated positive safety, tolerability and efficacy in both combination and monotherapy settings to date. Results from part 1 of RAINIER, the Company's ongoing dose optimization trial showed that 100% of patients achieved remission within 30 days of treatment. Mipletamig is an investigational drug product that have not yet been approved by the U.S. FDA but is currently in early stages of clinical development. The Company's second clinical candidate, (5T4 x 4-1BB), is a first-in-class solid tumor bispecific targeting 5T4-expressing solid tumor cancers. Recent results from a dose escalation trial showed that 59% of patients (10/17) achieved stable disease including multiple patients with sustained stable disease for as long as 12 months. Aptevo's three preclinical candidates are advancing innovation in large solid tumor markets like prostate cancer and the entire pipeline is driven by two proprietary platforms that enable the efficient development of new, rationally designed molecules. With bispecific immunotherapies transforming oncology, this is the time to dive deeper into Aptevo's pioneering solutions. APVO is a client of RedChip Companies. Please read our full disclosure at About Aptevo Therapeutics Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ('orphan status') for AML according to the Orphan Drug Act. a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. To learn more about RedChip's products and services, please visit: Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of across multiple tumor types will continue to show clinical benefit, the possibility and timing of interim data readouts for statements related to Aptevo's cash position and balance sheet, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words 'may,' 'continue to,' 'believes,' 'knows,' 'expects,' 'optimism,' 'potential,' 'designed,' 'promising,' 'plans,' 'will' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine and the war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances. Contact: Dave Gentry RedChip Companies Inc. --END--
Yahoo
16-02-2025
- Business
- Yahoo
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / / February 15, 2025 / RedChip Companies announced today that an interview with Aptevo Therapeutics' (Nasdaq:APVO) President and CEO Marvin White, will air on RedChip's Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, Saturday, February 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interview in its entirety: In an exclusive interview, Marvin White, President and CEO of Aptevo, will appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's recent accomplishments and innovative approach to the development of bispecific immuno-oncology therapeutics that are differentiated by design. Lead candidate, Mipletamig (CD3 x CD123)targets AML (a $6.3B market) and has treated more than 100 patients across three clinical trials and consistently demonstrated positive safety, tolerability and efficacy in both combination and monotherapy settings to date. Results from part 1 of RAINIER, the Company's ongoing dose optimization trial showed that 100% of patients achieved remission within 30 days of treatment. Mipletamig is an investigational drug product that have not yet been approved by the U.S. FDA but is currently in early stages of clinical development. The Company's second clinical candidate, (5T4 x 4-1BB), is a first-in-class solid tumor bispecific targeting 5T4-expressing solid tumor cancers. Recent results from a dose escalation trial showed that 59% of patients (10/17) achieved stable disease including multiple patients with sustained stable disease for as long as 12 months. Aptevo's three preclinical candidates are advancing innovation in large solid tumor markets like prostate cancer and the entire pipeline is driven by two proprietary platforms that enable the efficient development of new, rationally designed molecules. With bispecific immunotherapies transforming oncology, this is the time to dive deeper into Aptevo's pioneering solutions. APVO is a client of RedChip Companies. Please read our full disclosure at About Aptevo Therapeutics Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of across multiple tumor types will continue to show clinical benefit, the possibility and timing of interim data readouts for statements related to Aptevo's cash position and balance sheet, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine and the war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances. Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ Miriam Weber MillerHead, Investor Relations & Corporate CommunicationsAptevo TherapeuticsEmail: IR@ or Millerm@ 206-859-6628 --END-- SOURCE: RedChip View the original press release on ACCESS Newswire Sign in to access your portfolio
